Compare $BRTX vs $MTNB | Chartloom

Compare

$BRTX vs $MTNB

BioRestorative Therapies Inc · Matinas BioPharma Holdings Inc

BRTX

BioRestorative Therapies Inc

MTNB

Matinas BioPharma Holdings Inc

Compare $BRTX vs $MTNB

Comparing BioRestorative Therapies Inc and Matinas BioPharma Holdings Inc

BRTXBioRestorative Therapies Inc

MTNBMatinas BioPharma Holdings Inc

BRTXBioRestorative Therapies Inc

Market cap

$49M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-8.5%

YTD performance

-92.2%

52W performance

-94.2%

FCF yield

-24.4%

MTNBMatinas BioPharma Holdings Inc

Market cap

$39M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-69.1%

52W performance

-89.8%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BRTX

MTNB

Detailed metrics comparison

BRTX

BioRestorative Therapies Inc

MTNB

Matinas BioPharma Holdings Inc

Market Cap

BRTX$49M

MTNB$39M

Enterprise Value

BRTX$46M

MTNB$39M

Price

BRTX$1.91

MTNB$2.87

P/E Ratio

BRTXN/A

MTNBN/A

P/S Ratio

BRTX135.98x

MTNB0.60x

EV/Sales

BRTX127.28x

MTNB0.43x

EV/EBITDA

BRTX0.00x

MTNB0.00x

P/B Ratio

BRTX0.98x

MTNB1.44x

P/FCF Ratio

BRTXN/A

MTNBN/A

EV/FCF

BRTX-3.83x

MTNB-6.00x

PEG Ratio

BRTXN/A

MTNBN/A

Forward P/E (NTM)

BRTXN/A

MTNBN/A

Forward P/S (NTM)

BRTXN/A

MTNBN/A

Revenue (TTM)

BRTX$358K

MTNB$0

Revenue Growth (YoY)

BRTX-8.5%

MTNBN/A

Forward Rev Growth

BRTX64.6%

MTNB0.0%

Gross Margin (TTM)

BRTX92.1%

MTNB0.0%

Operating Margin (TTM)

BRTX0.0%

MTNB0.0%

EBITDA Margin (TTM)

BRTX-3915.8%

MTNB0.0%

Net Margin (TTM)

BRTX-3089.3%

MTNB0.0%

FCF Margin (TTM)

BRTX-3324.3%

MTNBN/A

Net Income (TTM)

BRTX$-11M

MTNB$-3M

FCF (TTM)

BRTX$-12M

MTNB$-6M

EPS (TTM)

BRTX-$12.47

MTNB$0.00

ROE (TTM)

BRTX-42384.0%

MTNB-13745.0%

ROA (TTM)

BRTX-19330.0%

MTNB-9202.0%

ROIC (TTM)

BRTX-42384.0%

MTNB-13717.0%

Cash

BRTX$3M

MTNB$761K

Debt

BRTX$0

MTNB$6K

Net Cash/Debt

BRTX$3M

MTNB$755K

Current Ratio (TTM)

BRTX2.35x

MTNB0.85x

Quick Ratio (TTM)

BRTX2.23x

MTNB0.60x

Debt/Equity (TTM)

BRTX0.00x

MTNB0.00x

Debt/Assets (TTM)

BRTX0.0%

MTNB0.0%

Interest Coverage (TTM)

BRTXN/A

MTNBN/A

Net Debt/EBITDA (TTM)

BRTX0.00x

MTNB0.00x

Beta

BRTX0.80

MTNB2.20

52W Performance

BRTX-94.2%

MTNB-89.8%

YTD Performance

BRTX-92.2%

MTNB-69.1%

% from 52W High

BRTX-94.5%

MTNB-90.1%

% from 52W Low

BRTX9.1%

MTNB27.1%

Asset Turnover (TTM)

BRTX0.06x

MTNB0.09x

FCF Yield (TTM)

BRTX-24.4%

MTNB-16.3%

Earnings Yield (TTM)

BRTX-22.7%

MTNB-8.8%

Dividend Yield (TTM)

BRTXN/A

MTNBN/A

Rule of 40

BRTX-3,332.8

MTNB0.0

EV/GP/RG

BRTX2.12

MTNBN/A

Ticker research

View BRTX research View MTNB research

Metric	BRTX BioRestorative Therapies Inc	MTNB Matinas BioPharma Holdings Inc
Market & Valuation
Market Cap	$49M	$39M
Enterprise Value	$46M	$39M
Price	$1.91	$2.87
P/E Ratio	N/A	N/A
P/S Ratio	135.98x	0.60x
EV/Sales	127.28x	0.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	1.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.83x	-6.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$358K	$0
Revenue Growth (YoY)	-8.5%	N/A
Forward Rev Growth	64.6%	0.0%
Profitability
Gross Margin (TTM)	92.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3915.8%	0.0%
Net Margin (TTM)	-3089.3%	0.0%
FCF Margin (TTM)	-3324.3%	N/A
Net Income (TTM)	$-11M	$-3M
FCF (TTM)	$-12M	$-6M
EPS (TTM)	-$12.47	$0.00
ROE (TTM)	-42384.0%	-13745.0%
ROA (TTM)	-19330.0%	-9202.0%
ROIC (TTM)	-42384.0%	-13717.0%
Financial Health
Cash	$3M	$761K
Debt	$0	$6K
Net Cash/Debt	$3M	$755K
Current Ratio (TTM)	2.35x	0.85x
Quick Ratio (TTM)	2.23x	0.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.80	2.20
52W Performance	-94.2%	-89.8%
YTD Performance	-92.2%	-69.1%
% from 52W High	-94.5%	-90.1%
% from 52W Low	9.1%	27.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.09x
FCF Yield (TTM)	-24.4%	-16.3%
Earnings Yield (TTM)	-22.7%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-3,332.8	0.0
EV/GP/RG	2.12	N/A
Ticker research	View BRTX research	View MTNB research

Valuation

P/S Ratio

MTNB

0.60x

BRTX

135.98x

EV/FCF

MTNB

-6.00x

BRTX

-3.83x

Growth & revenue

Revenue Growth TTM

BRTX

-8.5%

Forward Revenue Growth

BRTX

64.6%

MTNB

0.0%

Profitability & performance

Gross Margin

BRTX

92.1%

MTNB

0.0%

ROE

MTNB

-13745.0%

BRTX

-42384.0%

FCF Yield %

MTNB

-16.3%

BRTX

-24.4%

52-Week Performance

MTNB

-89.8%

BRTX

-94.2%

Detailed metrics comparison

BRTX

BioRestorative Therapies Inc

MTNB

Matinas BioPharma Holdings Inc

Market Cap

BRTX$49M

MTNB$39M

Enterprise Value

BRTX$46M

MTNB$39M

Price

BRTX$1.91

MTNB$2.87

P/E Ratio

BRTXN/A

MTNBN/A

P/S Ratio

BRTX135.98x

MTNB0.60x

EV/Sales

BRTX127.28x

MTNB0.43x

EV/EBITDA

BRTX0.00x

MTNB0.00x

P/B Ratio

BRTX0.98x

MTNB1.44x

P/FCF Ratio

BRTXN/A

MTNBN/A

EV/FCF

BRTX-3.83x

MTNB-6.00x

PEG Ratio

BRTXN/A

MTNBN/A

Forward P/E (NTM)

BRTXN/A

MTNBN/A

Forward P/S (NTM)

BRTXN/A

MTNBN/A

Revenue (TTM)

BRTX$358K

MTNB$0

Revenue Growth (YoY)

BRTX-8.5%

MTNBN/A

Forward Rev Growth

BRTX64.6%

MTNB0.0%

Gross Margin (TTM)

BRTX92.1%

MTNB0.0%

Operating Margin (TTM)

BRTX0.0%

MTNB0.0%

EBITDA Margin (TTM)

BRTX-3915.8%

MTNB0.0%

Net Margin (TTM)

BRTX-3089.3%

MTNB0.0%

FCF Margin (TTM)

BRTX-3324.3%

MTNBN/A

Net Income (TTM)

BRTX$-11M

MTNB$-3M

FCF (TTM)

BRTX$-12M

MTNB$-6M

EPS (TTM)

BRTX-$12.47

MTNB$0.00

ROE (TTM)

BRTX-42384.0%

MTNB-13745.0%

ROA (TTM)

BRTX-19330.0%

MTNB-9202.0%

ROIC (TTM)

BRTX-42384.0%

MTNB-13717.0%

Cash

BRTX$3M

MTNB$761K

Debt

BRTX$0

MTNB$6K

Net Cash/Debt

BRTX$3M

MTNB$755K

Current Ratio (TTM)

BRTX2.35x

MTNB0.85x

Quick Ratio (TTM)

BRTX2.23x

MTNB0.60x

Debt/Equity (TTM)

BRTX0.00x

MTNB0.00x

Debt/Assets (TTM)

BRTX0.0%

MTNB0.0%

Interest Coverage (TTM)

BRTXN/A

MTNBN/A

Net Debt/EBITDA (TTM)

BRTX0.00x

MTNB0.00x

Beta

BRTX0.80

MTNB2.20

52W Performance

BRTX-94.2%

MTNB-89.8%

YTD Performance

BRTX-92.2%

MTNB-69.1%

% from 52W High

BRTX-94.5%

MTNB-90.1%

% from 52W Low

BRTX9.1%

MTNB27.1%

Asset Turnover (TTM)

BRTX0.06x

MTNB0.09x

FCF Yield (TTM)

BRTX-24.4%

MTNB-16.3%

Earnings Yield (TTM)

BRTX-22.7%

MTNB-8.8%

Dividend Yield (TTM)

BRTXN/A

MTNBN/A

Rule of 40

BRTX-3,332.8

MTNB0.0

EV/GP/RG

BRTX2.12

MTNBN/A

Ticker research

View BRTX research View MTNB research

Metric	BRTX BioRestorative Therapies Inc	MTNB Matinas BioPharma Holdings Inc
Market & Valuation
Market Cap	$49M	$39M
Enterprise Value	$46M	$39M
Price	$1.91	$2.87
P/E Ratio	N/A	N/A
P/S Ratio	135.98x	0.60x
EV/Sales	127.28x	0.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.98x	1.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.83x	-6.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$358K	$0
Revenue Growth (YoY)	-8.5%	N/A
Forward Rev Growth	64.6%	0.0%
Profitability
Gross Margin (TTM)	92.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3915.8%	0.0%
Net Margin (TTM)	-3089.3%	0.0%
FCF Margin (TTM)	-3324.3%	N/A
Net Income (TTM)	$-11M	$-3M
FCF (TTM)	$-12M	$-6M
EPS (TTM)	-$12.47	$0.00
ROE (TTM)	-42384.0%	-13745.0%
ROA (TTM)	-19330.0%	-9202.0%
ROIC (TTM)	-42384.0%	-13717.0%
Financial Health
Cash	$3M	$761K
Debt	$0	$6K
Net Cash/Debt	$3M	$755K
Current Ratio (TTM)	2.35x	0.85x
Quick Ratio (TTM)	2.23x	0.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.80	2.20
52W Performance	-94.2%	-89.8%
YTD Performance	-92.2%	-69.1%
% from 52W High	-94.5%	-90.1%
% from 52W Low	9.1%	27.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.09x
FCF Yield (TTM)	-24.4%	-16.3%
Earnings Yield (TTM)	-22.7%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-3,332.8	0.0
EV/GP/RG	2.12	N/A
Ticker research	View BRTX research	View MTNB research